Key result
Levosimendan linked to ~88 fewer intubation hours in low cardiac output syndrome after pericardiectomy.
Why the study?
Low cardiac output syndrome after pericardiectomy carries high morbidity and mortality, prompting evaluation of levosimendan in patients with constrictive pericarditis.
Does levosimendan improve postoperative outcomes in patients with constrictive pericarditis developing low cardiac output syndrome after pericardiectomy?
Cohort (n=32)
No
Does levosimendan improve postoperative outcomes in patients with constrictive pericarditis developing low cardiac output syndrome after pericardiectomy?
Levosimendan may enhance postoperative recovery by reducing intubation time, vasopressor use, and ICU/hospital stay in patients developing low cardiac output syndrome after pericardiectomy.
Answers are grounded in this paper and cite their sources.
May support levosimendan for faster recovery post-pericardiectomy; leaves open confirmation in randomized trials.
Background: Low cardiac output syndrome (LCOS) after pericardiectomy is associated with high morbidity and mortality. This study aimed to assess the effect of levosimendan on postoperative LCOS in the patients with constrictive pericarditis. Methods: Patients were retrospectively enrolled, and those receiving the treatment of levosimendan were assigned in the LEVO (+) group, and others were in the LEVO (-) group. Postoperative outcomes including durations of intubation, vasoactive agents using, ICU stay, hospital stay and mortality were compared between the two groups. Results: A total of 32 patients were eligible for analysis, 19 of whom were in the LEVO (+) group, and 13 of whom were in the LEVO (-) group. The LEVO (+) group was associated with shorter postoperative duration of intubation (P < 0.001), vasopressor using (P = 0.006), ICU stay (P = 0.001) and hospital stay (P = 0.042), and less incidence of acute liver or kidney injury (P = 0.046). There were no significant differences in 30-day mortality and 1-year mortality between the LEVO (+) group and the LEVO (-) group. The prevalence of adverse events in the LEVO (+) group was acceptable. Conclusion: Levosimendan could be administered in the patients with constrictive pericarditis developing LCOS after pericardiectomy to enhanced postoperative recovery.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2024) conducted a cohort in Low cardiac output syndrome (LCOS) after pericardiectomy for constrictive pericarditis (n=32). Levosimendan vs. No levosimendan was evaluated on Postoperative duration of intubation (hours) (p=<0.001). Levosimendan reduced the median duration of postoperative intubation and ICU stay compared to control in patients with low cardiac output syndrome after pericardiectomy.
Synapse has enriched 10 related papers. Consider them for comparative context: